These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38929666)

  • 61. Target-Oriented Classification of Triple-negative Breast Cancer.
    Mizumoto S; Inubushi S; Miki M; Nakamura H; Baba M; Yamashita Y; Yamamoto M; Inoue S; Tanino H; Kunihisa T
    Anticancer Res; 2023 Nov; 43(11):5067-5072. PubMed ID: 37909966
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.
    Guo L; Li W; Zhu X; Ling Y; Qiu T; Dong L; Fang Y; Yang H; Ying J
    Springerplus; 2016; 5(1):805. PubMed ID: 27390646
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
    Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
    [No Abstract]   [Full Text] [Related]  

  • 65. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The expression of androgen receptor in triple-negative breast cancer and the effect of a traditional Chinese medicine formula on disease-free survival.
    Yu L; Yu Q; Xu C; Wang M; Song J; Gao X
    Gland Surg; 2022 Nov; 11(11):1772-1783. PubMed ID: 36518802
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
    Sanuki F; Mikami Y; Nishimura H; Fujita Y; Monobe Y; Nomura T; Taira N; Moriya T
    Breast Cancer; 2023 Nov; 30(6):1041-1053. PubMed ID: 37642903
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer.
    Haq ATA; Yang PP; Jin C; Shih JH; Chen LM; Tseng HY; Chen YA; Weng YS; Wang LH; Snyder MP; Hsu HL
    Theranostics; 2024; 14(5):2167-2189. PubMed ID: 38505617
    [No Abstract]   [Full Text] [Related]  

  • 69. Expression of PD-L1 in Early-Stage Invasive Breast Carcinoma and Its Relation to Tumor-Infiltrating Lymphocytes.
    Amin NH; Abou-Bakr AA; Eissa S; Nassar HR; Eissa TS; Mohamed G
    Asian Pac J Cancer Prev; 2022 Mar; 23(3):1091-1102. PubMed ID: 35345385
    [TBL] [Abstract][Full Text] [Related]  

  • 70. GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer.
    Cheng SW; Chen PC; Lin MH; Ger TR; Chiu HW; Lin YF
    Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33916322
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis.
    Wang C; Pan B; Zhu H; Zhou Y; Mao F; Lin Y; Xu Q; Sun Q
    Oncotarget; 2016 Jul; 7(29):46482-46491. PubMed ID: 27374089
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
    Kagihara JA; Andress M; Diamond JR
    Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733
    [TBL] [Abstract][Full Text] [Related]  

  • 73. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
    Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
    Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
    Mangia A; Saponaro C; Vagheggini A; Opinto G; Centonze M; Vicenti C; Popescu O; Pastena M; Giotta F; Silvestris N
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540486
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
    Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
    Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
    Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) EXPRESSION IN TRIPLE NEGATIVE BREAST CANCER CASES IN BENIN CITY.
    Owolabi DO; Olu-Eddo AN; Ekanem VJ; Udoh MO; Ogunbiyi JO; Obaseki DE; Obahiagbon I; Asogwa K; Nwagoh B; Aniume O; Ugiagbe EE; Forae GD; Imasogie DE
    West Afr J Med; 2023 Dec; 40(12 Suppl 1):S35. PubMed ID: 38070139
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
    Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
    J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population.
    Gajaria PK; Gupta MR; Patil A; Desai SB; Shet TM
    Indian J Pathol Microbiol; 2021; 64(4):664-670. PubMed ID: 34673583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.